Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.

Article  PubMed  PubMed Central  Google Scholar 

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.

Article  CAS  PubMed  Google Scholar 

Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamazaki F. Psoriasis: comorbidities. J Dermatol. 2021;48(6):732–40.

Article  PubMed  PubMed Central  Google Scholar 

Weber B, Merola JF, Husni ME, Di Carli M, Berger JS, Garshick MS. Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics. Curr Atheroscler Rep. 2021;23(11):67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orlando G, Molon B, Viola A, Alaibac M, Angioni R, Piaserico S. Psoriasis and cardiovascular diseases: an immune-mediated cross talk? Front Immunol. 2022;13:868277.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014–24.

Article  PubMed  Google Scholar 

Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650-656.e3.

Article  PubMed  PubMed Central  Google Scholar 

Jing X, Zhuyuan W, Aijun C, Jianxia X, Kun H, Ping W. Association of psoriasis with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1175477.

Article  PubMed  Google Scholar 

Conti A, Giovannini L, Mandel VD, et al. Chronic kidney disease in psoriasis: a cohort study. J Dtsch Dermatol Ges. 2020;18(5):438–45.

PubMed  Google Scholar 

Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ. 2013;347:f5961.

Article  PubMed  PubMed Central  Google Scholar 

Armstrong A, Xia Q, John AR, Patel V, Seigel L. Treatment patterns for targeted therapies, non-targeted therapies, and drug holidays in patients with psoriasis. Dermatol Ther (Heidelb). 2022;12(9):2087–103.

Article  PubMed  Google Scholar 

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–15.

Article  CAS  PubMed  Google Scholar 

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

Article  PubMed  Google Scholar 

Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535.

PubMed  Google Scholar 

Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19(1):1–13.

Article  CAS  PubMed  Google Scholar 

Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628–37.

Article  CAS  PubMed  Google Scholar 

Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158–66.

Article  CAS  PubMed  Google Scholar 

Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535.

PubMed  Google Scholar 

Garshick MS, Berger JS. Psoriasis and cardiovascular disease—an ounce of prevention is worth a pound of cure. JAMA Dermatol. 2022;158(3):239–41.

Article  PubMed  PubMed Central  Google Scholar 

Lee E, Han JH, Bang CH, et al. Risk of end-stage renal disease in psoriatic patients: real-world data from a nationwide population-based cohort study. Sci Rep. 2019;9(1):16581.

Article  PubMed  PubMed Central  Google Scholar 

Shear NH, Betts KA, Soliman AM, et al. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021;85(3):572–81.

Article  CAS  PubMed  Google Scholar 

Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–75.

Article  CAS  PubMed  Google Scholar 

Pina Vegas L, Le Corvoisier P, Penso L, Paul M, Sbidian E, Claudepierre P. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology (Oxford). 2022;61(4):1589–99.

Article  PubMed  Google Scholar 

Knowles L, Nadeem N, Chowienczyk PJ. Do anti-tumour necrosis factor-α biologics affect subclinical measures of atherosclerosis and arteriosclerosis? A systematic review. Br J Clin Pharmacol. 2020;86(5):837–51.

Article  PubMed  PubMed Central  Google Scholar 

Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.

Article  PubMed  Google Scholar 

Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535.

PubMed  Google Scholar 

Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–71.

Article  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Article  PubMed  Google Scholar 

Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9(7):e99682.

Article  PubMed  PubMed Central  Google Scholar 

Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704–10.

Article  CAS  PubMed  Google Scholar 

Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–32 (Discussion 1632).

Article  CAS  PubMed  Google Scholar 

Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–92.

Article  CAS  PubMed